SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read ...

San Diego’s Illumina is the world leader in gene sequencing technology — the ability to read and record DNA. Now, the billion-dollar company is buying another in a bid to expand its portfolio in ...

Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced the launch of BioInsight, a ...

Illumina, which specializes in DNA sequencing, will work on samples representing 1,300 species in the San Diego Zoo Wildlife ...

Combined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages ...

When Illumina (ILMN) announced its acquisition of Fluent BioSciences, it did not say how much it shelled out for the privately held single-cell technology developer in a deal that catapulted the ...

In early February 2026, Illumina reported past fourth-quarter 2025 revenue of US$1,159 million and net income of US$334 million, alongside full-year 2025 net income of US$850 million and new 2026 ...

During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...

At its ongoing genomics forum, narrow-moat Illumina finally gave investors a glimpse of its new product pipeline, which could help it stave off new entrants in its legacy sequencing business. While ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $128.8, a high estimate of $170.00, and a low estimate of $100.00. This current ...